Thromboembolic Complications in Mild Covid-19 Cases

NCT06695377 | Completed

• 1 other identifier: 02.12.2022.1652
• Study Type: observational
• Target: 961
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of the study is to investigate the frequency of thromboembolic complications and the factors influencing them in COVID-19 cases that did not require hospitalization. For this purpose, patients registered at two different family health centers in Istanbul were retrospectively screened, and their status regarding post-COVID-19 thromboembolic events was recorded. The sociodemographic characteristics, medical history, COVID-19 treatments received, comorbidities, and current medications of all patients were examined and compared with the occurrence of complications.

Conditions

COVID 19; Thromboembolic and Bleeding Complications; Thromboembolism, Venous; Post COVID-19

Keywords

COVID 19; thromboembolism; thromboembolic complications; pulmonary embolism; deep venous thrombosis

Outcome Measures

Primary Outcomes (3)

• The frequency of thromboembolic complications in COVID-19 patients not requiring hospitalization.

  Patients registered at a family health center were retrospectively reviewed, and those with a history of COVID-19 PCR positivity who had been followed up as outpatients were included. The occurrence of venous or arterial thromboembolism within the first 6 months after infection was recorded from their medical reports, and the frequency was calculated.

  january-june 2022

• The relationship between patients' comorbidities and the occurrence of thromboembolic events post-COVID.

  The patients' existing chronic conditions from the time of their COVID-19 infection were recorded by reviewing the family medicine system. The presence of chronic diseases was then analyzed in comparison to the occurrence of thrombosis within the first 6 months following COVID-19 infection.

  january-june 2022

• The relationship between patients' medications and the occurrence of thromboembolic events post-COVID.

  The medications regularly used by patients for their chronic conditions since the time of their COVID-19 infection were noted by reviewing records in the family medicine system. These medications were then analyzed in comparison to the occurrence of thrombosis within the first 6 months following COVID-19 infection.

  january-june 2022

Study Arms (1)

Patients with a PCR-confirmed COVID-19 diagnosis who were followed up on an outpatient basis

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients over the age of 18 who were registered at family health centers in two different districts of Istanbul and had a confirmed COVID-19 infection verified by PCR test between January 1, 2022, and June 30, 2022, were included in the study.

You may qualify if:

• Being over 18 years of age
• Having had a confirmed COVID-19 infection verified by a PCR test
• Being monitored at a family health center without requiring hospitalization during the COVID-19 course
• Having at least 6 months elapsed since the infection
• Availability of the patient's medical records
• Absence of any language barrier or health issue that would prevent communication with the patient

You may not qualify if:

• Being under 18 years of age
• Having had less than 6 months since the COVID-19 infection
• Presence of any condition that prevents communication with the patient
• Incomplete or missing medical records of the patient
• History of hospitalization due to COVID-19 infection

Sponsors & Collaborators

• Marmara University Pendik Training and Research Hospital: lead

Study Sites (1)

Marmara University Medical School

Istanbul, Turkey (Türkiye)

Location

Related Publications (3)

• Azevedo-Cerqueira A, Torrao Pinheiro P, Oliveira J, Manuel-Marques M, Rocha Neves J. Risk Of Venous Thrombosis In The Primary Care Setting During The Covid-19 Pandemic. Port J Card Thorac Vasc Surg. 2023 Apr 4;30(1):43-47. doi: 10.48729/pjctvs.310.

  PMID: 37029943 BACKGROUND

• Katsoularis I, Fonseca-Rodriguez O, Farrington P, Jerndal H, Lundevaller EH, Sund M, Lindmark K, Fors Connolly AM. Risks of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19: nationwide self-controlled cases series and matched cohort study. BMJ. 2022 Apr 6;377:e069590. doi: 10.1136/bmj-2021-069590.

  PMID: 35387772 BACKGROUND

• Usanma Koban B, Celik O, Sur Unal U, Uzuner A. Assessing the Burden of Thromboembolic Complications in Outpatient COVID-19 Cases: A Focused Study on Patients Followed in Primary Care. Can J Infect Dis Med Microbiol. 2025 Jul 24;2025:7242450. doi: 10.1155/cjid/7242450. eCollection 2025.

  PMID: 40747374 DERIVED

MeSH Terms

Conditions

COVID-19; Venous Thromboembolism; Thromboembolism; Pulmonary Embolism; Venous Thrombosis

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases; Embolism and Thrombosis; Vascular Diseases; Cardiovascular Diseases; Embolism; Thrombosis

Study Officials

• Buğu Usanma Koban

  Marmara University Medical Faculty

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: MD, PhD

Study Record Dates

• First Submitted: November 13, 2024
• First Posted: November 19, 2024
• Study Start: January 1, 2022
• Primary Completion: June 30, 2022
• Study Completion: September 30, 2022
• Last Updated: November 19, 2024

Record last verified: 2024-11

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)